Impella 5.5 在严重心源性休克中的支持:西班牙心脏移植中心首个多中心队列结局
平均支持时长16天,超过三分之一的移植来自可控性循环死亡后捐献供者。
要点
- Impella 5.5主要用于严重心源性休克的临时机械循环支持,在本队列中主要桥接至心脏移植。
- 46%患者需额外支持(主要为VA-ECLS),平均支持时长16天。
核心结论
- 在心脏移植导向的医疗体系中,Impella 5.5用于严重心源性休克的临时机械循环支持,主要与心脏移植相关。
- 结局与INTERMACS分级密切关联,反映基线严重程度和患者选择差异。
- 与国际登记数据的比较仅为描述性。
研究设计与样本
- 回顾性多中心观察性研究,纳入在具有活跃心脏移植项目的医院中连续接受Impella 5.5支持的患者。
- 记录基线特征、INTERMACS分级、额外支持、并发症、支持时长及院内死亡率,并按INTERMACS分级分析结局。
主要发现
- 46%患者需要额外支持,主要为VA-ECLS。
- 主要临床轨迹为心脏移植(68.8%),与国际系列中长期机械支持与移植分布更均匀形成对比。
- 平均支持时长16天,超过三分之一的移植来自可控性DCD供者。
临床怎么用
- 对于严重心源性休克患者,Impella 5.5可作为临时机械循环支持,尤其在心脏移植导向的中心。
- INTERMACS分级有助于风险分层和患者选择,1级患者院内死亡率最高。
- 需注意近半数患者需额外支持(如VA-ECLS),并关注设备相关并发症。
局限性
- 回顾性观察性设计,比较仅为描述性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Impella 5.5 is an established temporary mechanical circulatory support (tMCS) device for severe cardiogenic shock. Spain, characterized by high heart transplant activity and increasing use of controlled donation after circulatory death (DCD), provides a relevant setting to evaluate its use and outcomes. We aimed to describe clinical characteristics, trajectories, and outcomes of Impella 5.5 support in the first Spanish multicentre cohort from heart transplant centres. METHODS: Retrospective multicentre observational study including consecutive patients supported with Impella 5.5 in hospitals with active heart transplant programmes. Baseline characteristics, Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profile, additional support, complications, support duration, and in-hospital mortality were recorded. Outcomes were analysed across INTERMACS profiles. RESULTS: Ninety-three patients were included (33 INTERMACS 1, 37 INTERMACS 2, 23 INTERMACS 3). Additional support was required in 46%, mainly venoarterial extracorporeal life support (VA-ECLS). Device-related complications were reported as event frequencies. The predominant clinical trajectory was heart transplantation (68.8%), contrasting with international series in which long-term mechanical support and transplantation are more evenly distributed. In-hospital mortality was 43%, with a clear gradient across INTERMACS profiles 1-3 (60.6%, 37.8%, and 26.1%, respectively; P = .013). Mean support duration was 16 days, and more than one-third of transplants were from controlled DCD donors. CONCLUSIONS: Impella 5.5 was used as tMCS in severe cardiogenic shock and was predominantly associated with heart transplantation in a transplant-oriented healthcare system. Outcomes were closely associated with INTERMACS profile, reflecting differences in baseline severity and patient selection. Comparisons with international registries are descriptive only.
引用
- Martínez-Comendador JM, Martín Gutiérrez E, Ortiz Berbel D, et al. Impella 5.5 Support in Severe Cardiogenic Shock: Outcomes From the First Spanish Multicentre Cohort in Heart Transplant Centres. Interdiscip Cardiovasc Thorac Surg. 2026. PMID: 42127978. doi:10.1093/icvts/ivag137
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。